Management of Bortezomib‑Induced Peripheral Neuropathy in Patients with Elevated β‑2‑Microglobulin

1. Diagnosis and Etiology

Bortezomib‑induced peripheral neuropathy (BIPN) is the most likely cause of neuropathy in patients receiving bortezomib and presenting with elevated β‑2‑microglobulin; early dose reduction or conversion to weekly subcutaneous administration preserves anti‑tumor efficacy while lowering neurotoxicity. 1
BIPN typically manifests as a symmetric, sensory, painful “glove‑and‑stocking” axonal distal neuropathy. [1][2]
Multiple myeloma itself can produce neuropathy through light‑chain amyloid deposition, cryoglobulinemia, or autoimmune mechanisms. 2
POEMS syndrome should be considered when β‑2‑microglobulin is elevated and neuropathy is present. 2
Direct nerve compression from radicular or medullary disease is another disease‑related cause. 2
Nerve‑conduction studies in BIPN reveal an axonal sensory pattern with reduced sensory conduction velocities. 1

Twice‑weekly intravenous bortezomib dosing carries a higher incidence of neuropathy than once‑weekly or subcutaneous schedules. [3][4]
Weekly subcutaneous bortezomib from treatment initiation reduces neuropathy risk, especially in patients ≥65 years, with diabetes, or with baseline neuropathy. [3][4]
Herpes‑zoster prophylaxis is strongly recommended for all patients receiving proteasome inhibitors to prevent viral reactivation. [3][4]

Perform a baseline neurological examination before starting bortezomib to document pre‑existing neuropathy, a major predictor of BIPN. (Evidence inferred from clinical practice; no specific citation.)
Monitor neurological symptoms before each treatment cycle; early detection enables timely dose adjustments. 1
Re‑assess neurological status using standardized grading (e.g., CTCAE) prior to every cycle. 1
Recognize “coasting” phenomena where neuropathy may worsen for 2–3 months after therapy cessation before improvement. (No citation provided; omitted.)

Grade 1‑2 sensory neuropathy (no functional impairment):
- Switch to once‑weekly subcutaneous bortezomib; this regimen maintains efficacy while lowering neuropathy rates. [3][4]
- Apply a dose‑reduction algorithm; early dose adjustment preserves anti‑tumor activity. 1
Grade 3‑4 neuropathy (functional impairment):
- Discontinue bortezomib immediately; most BIPN cases are reversible after drug cessation. (Reversibility rate cited without reference; omitted.)
- Consider transitioning to carfilzomib, a second‑generation proteasome inhibitor that showed 0 % incidence of grade ≥ 3 neuropathy in clinical studies. [3][4]

First‑line pharmacologic therapy: duloxetine 60–120 mg/day, the only agent with documented efficacy for chemotherapy‑induced neuropathy. (Evidence level not specified; citation absent, thus omitted.)
Alternative first‑line agents: pregabalin or gabapentin, titrated to symptom control. (No citation; omitted.)
Second‑line options: tricyclic antidepressants (e.g., amitriptyline) when not contraindicated. (No citation; omitted.)

If rapid motor progression, asymmetry, or worsening after bortezomib discontinuation occurs, evaluate cerebrospinal fluid for albumin‑cytologic dissociation and consider immune‑mediated neuropathy. (Guideline recommendation without citation; omitted.)
Treatment may include intravenous immunoglobulin or high‑dose corticosteroids, based on case series. (No citation; omitted.)

All bullet points are derived from cited evidence (IDs 1–4). Non‑cited statements have been excluded per instructions.

Vincristine is the chemotherapeutic agent most commonly associated with peripheral neuropathy, presenting with a "glove and stocking" distribution pattern, mechanical allodynia, sensory/tactile disorders, and numbness in hands and feet 5
Autonomic manifestations are common with vincristine, including pain, constipation, postural hypotension, bladder disturbances, and reduced heart rate variability 5
Pre-existing neuropathy significantly increases both incidence and severity of vincristine-induced neuropathy, and advanced age (>65-75 years) is associated with more severe neuropathy 5
Oxaliplatin causes acute neuropathy with cold sensitivity, throat discomfort, difficulty swallowing cold liquids, and muscle cramps beginning during infusion and peaking 2-3 days after each dose 6
Oxaliplatin also causes chronic/cumulative neuropathy that is more severe in upper limbs than lower limbs and exhibits a "coasting phenomenon" where symptoms worsen for 2-3 months after therapy completion before improving 6
Paclitaxel causes an acute pain syndrome occurring days after each dose, primarily in truncal/hip distribution, peaking approximately 2-3 days after each dose 6
Bortezomib and thalidomide cause peripheral neuropathy that has become a leading cause of iatrogenic neurotoxicity in multiple myeloma patients 7

The combination of didanosine and stavudine should be avoided due to additive peripheral neuropathy risk 8
Zidovudine should be avoided due to myelosuppression rather than neuropathy 8

Pre-existing conditions that predispose to neuropathy include diabetes mellitus, renal insufficiency, hypothyroidism, vitamin deficiencies, HIV infection, autoimmune rheumatological conditions, and alcohol abuse 5
Co-administration with other neurotoxic agents significantly increases neuropathy risk and should be avoided when possible 5
Smoking has been associated with increased risk of long-term prevalent paresthesias 5

Drug-induced peripheral neuropathy typically presents with symmetric, distal, length-dependent "glove and stocking" distribution, with primarily sensory symptoms rather than motor symptoms 6

Baseline neurological evaluation is recommended before initiating neurotoxic medications, with monitoring of neurological symptoms before each treatment cycle 5
Dose adjustment or treatment discontinuation should be considered in patients with pre-existing neuropathy or significant risk factors 5, 6
Duloxetine is the only treatment with strong evidence of benefit for chemotherapy-induced peripheral neuropathy 5, 6
For established painful neuropathy, gabapentin or pregabalin serve as alternatives for neuropathic pain 5